关键词: 尤瑞克林; 脑梗死; 治疗结果; 过敏反应

Abstract: Objective To evaluate the therapeutic effects of urinary kallidinogenase for acute cerebralinfarction.Methods Sixty patients with acute cerebral infarction were randomly divided into normaltreatment plus Urinary Kallidinogenase (UK, n=30) or normal treatment (Control, n=30). NationalInstitutes of Health Stroke Scale (NIHSS) and Barthel index of all patients were assessed beforeand 14d after the treatment, Barthel index was followed up 90d after the treatment. The adverseeffects were also recorded.Results After 14d, NIHSS of both UK and control groups were decreased as compared with thepretreatment(UK, 8.57±2.25 vs 15.32±2.16, P =0.003; control, 9.23±0.96 vs 14.76±1.93, P =0.012).The decrease of NIHSS in UK group was more significant than that in control group (P =0.023).No obvious change in Barthel index in two groups were identified. After 90d, Barthel index ofboth UK and control group were decreased as compared with the pretreatment(UK, 83.05±2.11 vs47.75±1.52, P =0.004; Control, 72.15±2.22 vs 50.25±0.23, P =0.022). The decrease of Barthel indexin UK group was more significant than that in control group (P =0.034). No obvious side effectsrelated to UK treatment were observed.Conclusion Urinary kallidinogenase can obviously improve neurologic impairment andprognosis of acute cerebral infarction with good tolerability.

Key words: Urinary Kallidinogenase; Brain infarction; Treament outcome; Anaphylaxis